NovoMedix’s clinical candidates have novel biological response profiles
NovoMedix discovers and develops proprietary small molecules that modulate key regulatory pathways
including Interleukin-11 (IL-11), mTORC1, p-AKT, p-Stat3, p-Erk, 𝛼-SMA and AMPK, which drive cancer,
fibrosis, and/or heart disease. While all are important, the main focus of NovoMedix is the inhibition
of IL-11, an emerging, compelling therapeutic target in both oncology and fibrosis. IL-11 is a
tumor-promoting cytokine that endows “hallmarks of cancer” activities such as survival, proliferation,
invasion, angiogenesis as well as metastasis, and also is increasingly recognized as a key determinant
of lung/liver fibrosis, inflammation, and epithelial dysfunctions.
NovoMedix’s technology platform consists of a library of oral small molecule IL-11 inhibitors with compelling data in animal models of cancer and fibrosis coupled with remarkable safety profiles. The company’s leading pre-clinical therapeutic candidates are NMX1 in oncology and NMX2 in fibrosis. In in vitro and in vivo animal models, NMX1 arrests tumor growth, prevents metastasis, and is synergistic with chemotherapy and checkpoint inhibitors. NMX2 has reversed lung/liver fibrosis in pre-clinical models, and also exhibits synergies with two of the leading anti-fibrotic drugs available today. Intriguingly, both of these first in class inhibitors have unique cardio-protective properties that protect the heart from inflammation, fibrosis, and cardiac failure in multiple disease animal models.
May 26, 2022
NovoMedix is the recipient of a Phase II SBIR grant from the National Heart, Lung, and Blood Institute division of the NIH (1R44HL164314) titled: Novel Small Molecules for Protection Against Doxorubicin Cardiotoxicity in TNBC to further the development of clinical candidates that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.
January 20, 2022
NovoMedix is the recipient of an Innovative Concept Award funded by the National Cancer Institute (75N91022C00001), titled: Novel Small Molecule Inhibitors for the Treatment of Rhabdomyosarcoma.
November 5, 2021
NovoMedix will participate in the upcoming Life Sciences Summit (LSS) on November 9-10, 2021. LSS is an early stage investor and business development conference that highlights innovation that connects emerging biotech companies and academic innovators with the capital and strategic partners they will need to move new discoveries through clinical development. The conference features corporate presentations by promising young companies with transformative science that targets unmet medical needs.
September 1, 2021
NovoMedix is the recipient of an Phase I SBIR Grant funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (award Number 1R43HL160460) titled: Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease.